drugset / Trial / NCT02883426
Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-01-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV) | Vaccine | 1e+07 unknown | Intranasal |
| Background | H3N2v inactivated subvirion influenza vaccine | Vaccine | 15 ug | Intramuscular |